English: Thank you. On the second dose, without affecting the wider roll-out, we're already planning for the delivery of second doses, which - . In, literally, the coming few weeks we'll start to see more people getting their second dose, and those numbers will increase, because, as you'll know, in the first three to four weeks, we had lower numbers of people being vaccinated compared to what we're doing within this week. Our ability then to keep on going at the first dose rate we're currently doing will be affected by the overall amount of supply. So, we're going to need to think about making sure we have the right vaccine available for the second dose - so people who have had Pfizer should get Pfizer for the second dose, fewer concerns and issues about AstraZeneca, and we'll then need to know what then is left for us to deliver in terms of new first doses. So, again, it's a matter of supply, as well as then, going back to Angela Burns's point, about making use of the wider primary care team - so, our pharmacists - and our ability to then deliver an even bigger programme. If we have the supply to do that, we'll need to make use of that wider team in primary care. On the European Union and the vaccine, I think there's wide recognition, however you feel about the European Union, that the last week or two has not been great from an EU point of view. It was extraordinarily unhelpful in the way that issue was presented. I think common sense has now prevailed. Because we actually all need each other - both about travel, because, actually, coronavirus was largely imported to Wales when Brits went to Europe for holidays and came back in January, February last year; the February half-term was a significant importation event from travel directly from Europe, not from China. So, actually, those patterns of travel aren't going to be significantly different in the future, with future threats. It's also just the case that we are already getting vaccine from Europe, so we actually need good relationships with European partners to make sure that we're able to see vaccines cross international borders, just as the supply of AstraZeneca, some of which is already manufactured here in Wales. And your question about vaccine production in Wales - of course, AstraZeneca supply and fill is in Wrexham already. So, we already have some of that manufacture, and one of the new candidate vaccines has a vaccination production base in Scotland. So, the UK already has vaccination production within it, but that in itself isn't going, I think, to deliver the sort of certainty that we'd want. So, we still need a very practical and grown-up relationship with European production centres, as well as pharmaceutical companies that have bases in more than one part of Europe. And, when it comes to vaccine resistance, it's one of the things that, I think, has come up before. So, it's certainly a part of what our scientists look at, as well as researchers in individual companies looking to develop the next vaccines. And capacity - capacity has sprung up because of the way we've been able to move and use our primary care team. Vaccinations are normally undertaken primarily by primary care in any event. The thing about our highly successful immunisation programmes for children and young people around the flu campaign - well, it's primary care that does that, whether in a general practice or, indeed, in a pharmacy, or health visitors and others who will go and visit people at the earliest of ages. So, we're never going to have, if you like, a permanent structure of vaccination centres. If that were the case, then we'd be living with threats on a daily basis forever and a day. But, if we're needed to flex up again, I think what has been shown is that primary care is remarkably flexible and extraordinarily willing to protect people they care for on a regular basis, and I'm very grateful for all they've done.
Welsh: Diolch. O ran yr ail ddosau, heb effeithio ar y cyflwyno yn ehangach, rydym ni eisoes yn bwriadu darparu ail ddosau - . Yn ystod yr wythnosau nesaf, yn llythrennol, fe fyddwn ni'n dechrau gweld mwy o bobl yn cael eu hail ddos nhw, ac fe fydd y niferoedd hynny'n cynyddu, oherwydd, fel y gwyddoch, yn ystod y tair i bedair wythnos gyntaf, fe gawsom ni niferoedd llai o bobl yn cael eu brechu o'i gymharu â'r wythnos hon. Fe fydd cyfanswm y cyflenwad yn effeithio ar ein gallu ni i barhau i fynd ar yr un gyfradd a'r dos cyntaf fel rydym ni'n gwneud ar hyn o bryd. Felly, fe fydd angen inni ystyried sicrhau bod y brechlyn cywir ar gael gennym ar gyfer yr ail ddos - felly fe ddylai pobl sydd wedi cael Pfizer gael Pfizer eto ar gyfer yr ail ddos. Mae llai o bryderon a chwestiynau am AstraZeneca, ac fe fydd angen inni wybod wedyn beth sydd ar ôl inni ar gyfer cyflawni o ran dosau cyntaf newydd. Felly, unwaith eto, mater o gyflenwad yw hyn, yn ogystal â dychwelyd at bwynt Angela Burns, ynghylch gwneud defnydd o'r tîm gofal sylfaenol ehangach - felly, ein fferyllwyr ni - a'n gallu ni i ddarparu rhaglen fwy byth wedi hynny. Os bydd y cyflenwad gennym i wneud hynny, fe fydd angen defnyddio'r tîm ehangach hwnnw ym maes gofal sylfaenol. O ran yr Undeb Ewropeaidd a'r brechlyn, rwy'n credu bod yna gydnabyddiaeth eang, beth bynnag yw eich barn chi o'r Undeb Ewropeaidd, nad yw'r wythnos neu'r pythefnos ddiwethaf wedi bod yn rhagorol o safbwynt yr UE. Roedd y ffordd y cyflwynwyd y mater hwnnw'n eithriadol o ddi-fudd. Rwy'n credu bod synnwyr cyffredin wedi cario'r dydd erbyn hyn. Gan fod ar bawb angen ein gilydd - o ran teithio hefyd, oherwydd, mewn gwirionedd, fe gafodd y coronafeirws ei fewnforio i Gymru i raddau helaeth pan aeth pobl o Brydain i Ewrop am wyliau a dod adref ym mis Ionawr a mis Chwefror y llynedd; roedd hanner tymor mis Chwefror yn ddigwyddiad arwyddocaol o ran mewnforio oherwydd teithio uniongyrchol o Ewrop, ac nid o Tsieina. Felly, mewn gwirionedd, nid yw'r patrymau hynny o deithio am fod yn wahanol iawn yn y dyfodol, gyda bygythiadau yn y dyfodol. Mae hefyd yn wir ein bod ni eisoes yn cael brechlyn o Ewrop, felly mae angen perthynas dda â phartneriaid Ewropeaidd er mwyn sicrhau ein bod ni'n gallu gweld brechlynnau yn croesi ffiniau rhyngwladol, yn union fel mae cyflenwad AstraZeneca, y caiff rhywfaint ohono ei gynhyrchu yma yng Nghymru eisoes. Ac mae eich cwestiwn chi am gynhyrchu brechlynnau yng Nghymru - wrth gwrs, mae gwaith cyflenwi a llenwi AstraZeneca yn Wrecsam yn barod. Felly, mae gennym ni rywfaint o'r gweithgynhyrchu hwnnw yma eisoes, ac mae gan un o'r darpar frechlynnau newydd sylfaen i gynhyrchu'r brechlyn yn yr Alban. Felly, mae'r DU eisoes yn cynhyrchu brechiadau ar ei thiriogaeth ei hun, ond nid yw hynny ynddo'i hun am roi'r math o sicrwydd y byddem ni'n dymuno ei gael yn fy marn i. Felly, fe fydd angen perthynas ymarferol ac aeddfed iawn arnom ni â chanolfannau cynhyrchu yn Ewrop, yn ogystal â chwmnïau fferyllol sydd â chanolfannau mewn mwy nag un rhan o Ewrop. Ac o ran ymwrthedd i frechlynnau, dyma un o'r pethau sydd wedi codi o'r blaen, rwy'n credu. Felly, mae hynny'n sicr yn rhan o'r hyn y mae ein gwyddonwyr ni'n ei ystyried, yn ogystal ag ymchwilwyr mewn cwmnïau unigol sy'n awyddus i ddatblygu'r brechlynnau nesaf. A chapasiti - mae'r capasiti i frechu niferoedd mawr wedi cynyddu oherwydd y ffordd yr ydym wedi gallu symud a defnyddio ein tîm gofal sylfaenol ni. Fel rheol, caiff brechiadau eu gweinyddu gan ofal sylfaenol yn bennaf, beth bynnag. O ystyried ein rhaglenni imiwneiddio hynod lwyddiannus ni ar gyfer plant a phobl ifanc yn sgil yr ymgyrch ffliw - wel, gofal sylfaenol sy'n gweinyddu'r rhain, boed hynny mewn practis cyffredinol neu, yn wir, mewn fferyllfa, neu ymwelwyr iechyd ac eraill a fydd yn mynd i ymweld â phobl o oedran cynnar iawn. Felly, ni fydd gennym strwythur parhaol o ganolfannau brechu byth, os mynnwch chi. Os byddai hynny'n wir, fe fyddem yn byw gyda bygythiadau i dragwyddoldeb. Ond, pe byddai angen inni fod yn fwy ystwyth eto, rwy'n credu mai'r hyn a gafodd ei brofi yw bod gofal sylfaenol yn hynod o hyblyg ac yn hynod o barod i amddiffyn y bobl y maen nhw'n gofalu amdanyn nhw'n gyson, ac rwy'n ddiolchgar iawn am bopeth y maen nhw wedi ei wneud.